A Prescription For Fairness : Fixing Drug Pricing And Access Plan
Too many families are burdened by the rising cost of medications they depend on. Our system rewards profit over public health, even when taxpayer dollars fund the science.
It's time to create a fair and transparent process that puts patients, not corporations, at the center of care. We can build a future where innovation and access go hand in hand—without compromising the health of Americans.
Essential Medicines Cap Act
Place a 15% Profit Margin Cap PER DOSE for life-saving or essential medications.
- Ensure affordability for patients who depend on these drugs
- Ensure companies disclose manufacturing / R & D Costs
- Shift costs down after R & D is recovered
EXAMPLES include medicines or treatments for :
Diabetes, Allergies, Asthma & Respiratory, HIV/AIDS, Infectious diseases, Mental Stability, Cancer Treatments
Global Price Fairness Act
Non-Essential, Brand-Name Drugs are capped at 1.5 - 2x Organization for Economic Cooperation and Development Countries.
- U.S. Drug prices are currently 2.8x than OECD Markets
- U.S. Brand Name Drug Prices are up to 4.22x OECD Markets
Raising foreign prices to reduce the rate change effect would be seen as market manipulation.
Public Research & Public Benefit Act
Public funds help develop essential drugs and these funds need to be tied to fairer drug prices.
- Guarantee affordable access for the public to medicines and treatments that are developed with public tax dollars.
- Set pricing reductions as a percentage of the total public investment compared to total R & D Costs
- When we align federal investment and innovation with public benefits, we all win
Medical Marketing Allocation Act
Disincentivize Medical Marketing by imposing an increased marketing tax and promoting a national medical journal
- Drugmakers and Treatment options that forgo advertising are included in a journal available at all Medical Offices, Courthouses, Digital, and Dial-In Services showcasing :
- Emerging Treatments
- Experimental Treatments
- Newly Approved Treatments
- Generic Treatments
- Pharmaceutical or Treatment companies pay a 15% Tax on money spent marketing to doctors or consumers
Generic Competition and Patent Integrity Act
Many brand-name drugs remain expensive long after their research costs are recovered because companies extend monopolies through legal loopholes and delay competition.
- End patent “evergreening” practices that allow companies to extend exclusivity through minor formulation changes that do not significantly improve treatment outcomes
- Accelerate generic and biosimilar approvals by expanding FDA fast-track review for drugs with little or no market competition
- Penalize anti-competitive “pay-for-delay” agreements where brand manufacturers pay generic companies to delay bringing lower-cost alternatives to market
Critical Medicines Supply and Manufacturing Act
America should never face shortages of life-saving medicines because production is concentrated overseas or supply chains break down.
- Expand domestic manufacturing incentives for essential medicines, active pharmaceutical ingredients, and critical drug components
- Create a national essential medicines reserve to prevent shortages of critical drugs used in emergency care and chronic disease treatment
- Require supply chain transparency so regulators and healthcare systems can identify risks and prevent shortages before they occur